Global Finasteride Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Finasteride Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Finasteride Market Size Growth Rate by Product
  • 1.4.2 1 mg Tablet
  • 1.4.3 5 mg Tablet
• 1.5 Market by End User
  • 1.5.1 Global Finasteride Market Size Growth Rate by End User
  • 1.5.2 Medical Uses
  • 1.5.3 Prostate Enlargement
  • 1.5.4 Prostate Cancer
  • 1.5.5 Scalp Hair Loss
  • 1.5.6 Excessive Hair Growth
  • 1.5.7 Transgender Women
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Finasteride Market Size
  • 2.1.1 Global Finasteride Revenue 2014-2025
  • 2.1.2 Global Finasteride Sales 2014-2025
• 2.2 Finasteride Growth Rate by Regions
  • 2.2.1 Global Finasteride Sales by Regions
  • 2.2.2 Global Finasteride Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Finasteride Sales by Manufacturers
  • 3.1.1 Finasteride Sales by Manufacturers
  • 3.1.2 Finasteride Sales Market Share by Manufacturers
  • 3.1.3 Global Finasteride Market Concentration Ratio (CR5 and HHI)
• 3.2 Finasteride Revenue by Manufacturers
  • 3.2.1 Finasteride Revenue by Manufacturers (2014-2019)
  • 3.2.2 Finasteride Revenue Share by Manufacturers (2014-2019)
• 3.3 Finasteride Price by Manufacturers
• 3.4 Finasteride Manufacturing Base Distribution, Product Types
  • 3.4.1 Finasteride Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Finasteride Product Type
  • 3.4.3 Date of International Manufacturers Enter into Finasteride Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Finasteride Sales by Product
• 4.2 Global Finasteride Revenue by Product
• 4.3 Finasteride Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Finasteride Breakdown Data by End User

6 North America

• 6.1 North America Finasteride by Countries
  • 6.1.1 North America Finasteride Sales by Countries
  • 6.1.2 North America Finasteride Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Finasteride by Product
• 6.3 North America Finasteride by End User

7 Europe

• 7.1 Europe Finasteride by Countries
  • 7.1.1 Europe Finasteride Sales by Countries
  • 7.1.2 Europe Finasteride Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Finasteride by Product
• 7.3 Europe Finasteride by End User

8 Asia Pacific

• 8.1 Asia Pacific Finasteride by Countries
  • 8.1.1 Asia Pacific Finasteride Sales by Countries
  • 8.1.2 Asia Pacific Finasteride Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Finasteride by Product
• 8.3 Asia Pacific Finasteride by End User

9 Central & South America

• 9.1 Central & South America Finasteride by Countries
  • 9.1.1 Central & South America Finasteride Sales by Countries
  • 9.1.2 Central & South America Finasteride Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Finasteride by Product
• 9.3 Central & South America Finasteride by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Finasteride by Countries
  • 10.1.1 Middle East and Africa Finasteride Sales by Countries
  • 10.1.2 Middle East and Africa Finasteride Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Finasteride by Product
• 10.3 Middle East and Africa Finasteride by End User

11 Company Profiles

• 11.1 Merck
  • 11.1.1 Merck Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Merck Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Merck Finasteride Products Offered
  • 11.1.5 Merck Recent Development
• 11.2 Actavis
  • 11.2.1 Actavis Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Actavis Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Actavis Finasteride Products Offered
  • 11.2.5 Actavis Recent Development
• 11.3 Sandoz
  • 11.3.1 Sandoz Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Sandoz Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Sandoz Finasteride Products Offered
  • 11.3.5 Sandoz Recent Development
• 11.4 Teva Pharmaceuticals
  • 11.4.1 Teva Pharmaceuticals Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Teva Pharmaceuticals Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Teva Pharmaceuticals Finasteride Products Offered
  • 11.4.5 Teva Pharmaceuticals Recent Development
• 11.5 Cipla
  • 11.5.1 Cipla Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Cipla Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Cipla Finasteride Products Offered
  • 11.5.5 Cipla Recent Development
• 11.6 RelonChem
  • 11.6.1 RelonChem Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 RelonChem Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 RelonChem Finasteride Products Offered
  • 11.6.5 RelonChem Recent Development
• 11.7 Dr. Reddy
  • 11.7.1 Dr. Reddy Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Dr. Reddy Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Dr. Reddy Finasteride Products Offered
  • 11.7.5 Dr. Reddy Recent Development
• 11.8 Accord Pharmaceuticals
  • 11.8.1 Accord Pharmaceuticals Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Accord Pharmaceuticals Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Accord Pharmaceuticals Finasteride Products Offered
  • 11.8.5 Accord Pharmaceuticals Recent Development
• 11.9 Henan Topfond
  • 11.9.1 Henan Topfond Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Henan Topfond Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Henan Topfond Finasteride Products Offered
  • 11.9.5 Henan Topfond Recent Development
• 11.10 Zhejiang CONBA Pharmaceutical
  • 11.10.1 Zhejiang CONBA Pharmaceutical Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Zhejiang CONBA Pharmaceutical Finasteride Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Zhejiang CONBA Pharmaceutical Finasteride Products Offered
  • 11.10.5 Zhejiang CONBA Pharmaceutical Recent Development
• 11.11 Shandong Renhetang Pharmaceutical
• 11.12 Guangdong Eashu Pharmacetical

12 Future Forecast

• 12.1 Finasteride Market Forecast by Regions
  • 12.1.1 Global Finasteride Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Finasteride Revenue Forecast by Regions 2019-2025
• 12.2 Finasteride Market Forecast by Product
  • 12.2.1 Global Finasteride Sales Forecast by Product 2019-2025
  • 12.2.2 Global Finasteride Revenue Forecast by Product 2019-2025
• 12.3 Finasteride Market Forecast by End User
• 12.4 North America Finasteride Forecast
• 12.5 Europe Finasteride Forecast
• 12.6 Asia Pacific Finasteride Forecast
• 12.7 Central & South America Finasteride Forecast
• 12.8 Middle East and Africa Finasteride Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Finasteride Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details